Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Science Times Observer.
Press releases published on May 8, 2025
Pasinex Announces Issuance of Failure to File Cease Trade Order
GlobeNewswire
·
May 8, 2025
TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Pasinex Resources Limited (CSE: PSE) (FSE: PNX) ("Pasinex" or the "Company") today announced that the British Columbia Securities Commission, as its principal regulator, has issued a Failure to File Cease Trade …
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy
GlobeNewswire
·
May 8, 2025
Zervimesine treatment slowed the rate of GA lesion growth by 28.6% compared to placebo Observed GA lesion area was reduced by 28.2% at 18 months compared to placebo Dry AMD results validate zervimesine’s potential across degenerative disease indications …
Kamari Pharma Announces Presentations at the 82nd Annual Meeting of the Society for Investigative Dermatology and the International Pachyonychia Congenita Consortium Symposium
GlobeNewswire
·
May 8, 2025
Preclinical results presented demonstrate KM-023 is a highly effective and selective oral TRPV3 inhibitor KM-023 normalized cells proliferation and differentiation in 3D pachyonychia congenita skin model and significantly reduced itch behavior and …
CoreCard Corporation Reports First Quarter 2025 Results
GlobeNewswire
·
May 8, 2025
NORCROSS, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- CoreCard Corporation (NYSE: CCRD) (“CoreCard” or the “Company”), the leading provider of innovative credit technology solutions and processing services to the financial technology and services market, …
Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
GlobeNewswire
·
May 8, 2025
CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a …
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™
GlobeNewswire
·
May 8, 2025
GAITHERSBURG, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced the …
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress
GlobeNewswire
·
May 8, 2025
On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025 Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexiguran ziclumeran (nex-z) in patients with hereditary …
MACOM Reports Fiscal Second Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
LOWELL, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- MACOM Technology Solutions Holdings, Inc. (“MACOM”) (Nasdaq: MTSI), a leading supplier of semiconductor products, today announced its financial results for its fiscal second quarter ended April 4, 2025. …
Cronos Group Reports 2025 First Quarter Results
GlobeNewswire
·
May 8, 2025
Net revenue in Q1 2025 increased by 28% year-over-year, 33% year-over-year net revenue growth on a constant currency basis PEACE NATURALS® retained its position as the number one cannabis brand in Israel1 Industry-leading balance sheet with $838 million in …
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 8, 2025
- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 in DM1 initiated to support potential …
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results
GlobeNewswire
·
May 8, 2025
Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal cancer (MSS CRC) Advancing multiple masked T cell …
Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 8, 2025
Dosing complete in the first two cohorts of INLIGHT trial in obesity of WVE-007 (INHBE siRNA), designed to induce healthy weight loss by reducing fat without impacting muscle; clinical data on track for 2H 2025 Dosing underway in second single dose cohort …
American Tungsten Corp. Announces Addition to Board of Directors
GlobeNewswire
·
May 8, 2025
Vancouver, BC, May 08, 2025 (GLOBE NEWSWIRE) -- American Tungsten Corp. (CSE:TUNG) (OTCQB:DEMRF) (FSE:RK9) (“American Tungsten” or the “Company”) announces today the appointment of James (Jim) Whittaker to the Board of Directors of the Company (the “Board …
Inspired Reports First Quarter 2025 Results
GlobeNewswire
·
May 8, 2025
First Quarter Revenue of $60.4 million, driven primarily by record Interactive revenue, up 49% year-over-year First Quarter Net Loss of $0.1 million and Adjusted Net Income of $3.8 million First Quarter Adjusted EBITDA of $18.4 million, up 19% from last …
Purple Garden Empowers Users With Trusted Psychic Guidance
GlobeNewswire
·
May 8, 2025
San Francisco, CA, May 08, 2025 (GLOBE NEWSWIRE) -- Purple Garden is a popular online platform that offers psychic readings to customers anytime and anywhere. The platform has been operating for several years and is considered an industry leader in online …
Lucinity Featured in Chartis Research FinCrime and Compliance 50 Ranking for 2025
GlobeNewswire
·
May 8, 2025
REYKJAVIK, Iceland, May 08, 2025 (GLOBE NEWSWIRE) -- Lucinity has been listed among the top 50 Financial Crime and Compliance (FCC) companies in the 2025 FCC50 ranking by Chartis Research. This recognition reflects Lucinity’s continued ability to deliver …
Theriva Biologics anuncia el precio de su oferta pública de 7,5 millones de dólares
GlobeNewswire
·
May 8, 2025
ROCKVILLE, Maryland, May 08, 2025 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha …
Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025
GlobeNewswire
·
May 8, 2025
ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS …
Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025
GlobeNewswire
·
May 8, 2025
WALTHAM, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 15, …
HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress
GlobeNewswire
·
May 8, 2025
$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and …